SENSEX    76992.77       181.87    |    NIFTY    23465.6       66.70 FAQ    |    Feedback
EQUITIES
DERIVATIVES
IPO
Gainers & Losers Value & Volume Toppers 52 Weeks High/Low Advances & Declines
New High-Low
Pre-Session Mid-Session End-Session Other Markets Market Beat Stock Alert
Hot Pursuit Foreign Markets Economy News Corporate News Corporate Results
Detailed Quotes Board of Directors Balance Sheet Profit & Loss Quarterly Results Historical Price
Financial Ratios Company Background Technical Chart
Announcements Book Closure Board Meetings Bonus Issues Rights Issues
De-Listed Shares Name Change Split of Face Value Market Turnover
FII Investments MF Investments ADR Prices World Indices
Forthcoming IPOs
Open IPOs
Closed IPOs
New Listing
Basis Of Allotment Draft Prospectus New Issue Monitor
Get Quotes
Gainers
Losers
Value Toppers Advances & Declines Ticker Spot
Ticker Futures Closing Price Technical Chart Commodity News MCX Currency Futures
Get Quotes NIFTY Futures Top Traded Value Top Quantity Most Active Contracts
FII Statistics Daily Settlement Price List of Underlyings Put Call Ratio Derivative Summary
All Index Futures Top Gainers Top Losers Most Active Put Most Active Call
Highest in OI Lowest in OI Increase in OI Decrease in OI
Hot Pursuit
Scrips, which has significant changes during the market hours for last one week.
Ipca Labs slides as Q4 PAT drops 22% YoY to Rs 60 cr
29-May-24   16:46 Hrs IST

However, revenue from operations jumped 34.49% year on year to Rs 2,033.01 crore in the quarter ended 31 March 2024.

Profit before tax tumbled 40.82% to Rs 76.60 crore in the March quarter from Rs 129.44 crore posted in Q4 FY23.

EBITDA before forex gain, other income and exceptional items stood at Rs 304.59 crore, registering a growth of 78% YoY.

During the quarter, total formulations were at Rs 1163.48 crore, up 12% YoY. Domestic stood at Rs 689.83 crore (up 13% YoY) and Exports came in at Rs 473.65 crore (up 9.48% YoY) in Q4 FY24.

On a full year basis, the company?s consolidated net profit rose 16.13% to Rs 547.35 crore on 23.39% increase in revenue to Rs 7,705.04 crore in FY24 over FY23.

Meanwhile, the firm?s board has recommended a final dividend of Rs 2 per equity share for the financial year ended 2023-24, subject to the approval of the shareholders.

Ipca Laboratories is an Indian multinational pharmaceutical company. It produces theobromine, acetylthiophene, and p-bromotoluene as active pharmaceutical ingredients (APIs). Ipca sells these APIs and their intermediates globally.

Powered by Capital Market - Live News

MARKETS
TODAY'S MARKET SECTOR
BSE NSE
Currencies
Currency EUR GBP INR USD
Europe (EUR) 1.00 0.84 90.05 1.08
United Kingdom (GBP) 1.19 1.00 106.71 1.28
India (INR) 0.01 0.01 1.00 0.01
United States (USD) 0.93 0.78 83.54 1.00
Market News << ALL News
  15-Jun-2024, (04:54 )  Jnk India bags order..
  15-Jun-2024, (04:39 )  CRISIL reaffirms rat..
  15-Jun-2024, (04:32 )  Biocon?s Andhra Prad..
  15-Jun-2024, (04:00 )  Swan Energy board OK..
 Commodities << ALL Commodities
   Attention Investor: Prevent unauthorized transactions in your trading / Demat account : Update your mobile number / e mail ids with your stock broker / deposit." | "No need to issue cheques by investors while subscribing to IPO.Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor’s account." | "KYC is one time exercise while dealing in securities markets- once KYC is done through a SEBI registered intermediary(broker, DP, Mutual Fund etc.) you need not undergo the same process again when you approach another intermediary."
   Disclaimer   |   BSE Disclosure  |  Privacy Policy   |   Investor Protection   |    Inactive Account   |  Vernacular Language: NSE | BSE   |   Feedback   |    PMLA Policy   |   Risk Management Policy   |   Insider Trading   |   Investor Grivenances   |   Investor Complaints   |   Investor Charter   |   Rules And Regulations   |   Broker Norms   |   Terms of Use    Policies & Procedures   |   Risk Disclosure   |   Do & Don’ts   |   Rights & Obligations
  
SEBI Registration No : INZ000267132   |   BSE Clearing No : 333   
   Copyright © 2011 All rights reserved by Jaysukhlal Jagjivan Stock Broking Pvt.Ltd Designed, Developed & Powered By CMOTS INFOTECH (ISO 9001:2015 certified)